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The discovery of human metapneumovirus and its implications for respiratory tract disease have empha-
sized the need for a sensitive, specific, and rapid assay to detect this virus in a clinical setting. It recently
became clear that human metapneumovirus can be grouped into at least four genetic lineages. Previously
described assays for the detection of human metapneumovirus were developed by using limited sequence
information and failed to detect viruses from all four genetic lineages with comparable sensitivities. Here we
describe the development and evaluation of a real-time reverse transcriptase PCR assay that detects human
metapneumovirus from the four known genetic lineages with equal specificities and sensitivities.
The isolation and characterization of a novel paramyxovirus,
human metapneumovirus (hMPV), were recently described
(13, 14). hMPV was first isolated from children suffering from
acute respiratory tract disease (13); however, infections in all
other age groups were later identified as well (2, 6, 12). The
virus has been circulating in humans for at least 50 years. The
clinical signs associated with hMPV infection appear to be
similar to those caused by human respiratory syncytial virus
(RSV), which is the most common cause of respiratory tract
disease in children (3, 4, 15, 17). hMPV appears to be respon-
sible for about 7 to 10% (3, 5, 8, 9, 11, 12, 15) of cases of acute
respiratory tract infections in infants. This relatively high inci-
dence of hMPV infections and the fact that hMPV-associated
disease may be severe have emphasized the need for a reliable,
sensitive, and rapid diagnostic test for the detection of this
virus.
In a diagnostic setting, PCR is generally accepted for the
detection of viral infections, particularly for viruses that are
difficult to isolate in cell cultures, such as hMPV. To date, four
distinct genetic lineages of hMPV have been described (16).
For the detection of hMPV, a single assay that is equally
sensitive for all four hMPV genetic lineages is preferred. Here
we describe the development and evaluation of a new and
sensitive real-time reverse transcriptase (RT) PCR (RT-PCR)
assay which meets these requirements and a comparison of this
assay with previously described assays.
MATERIALS AND METHODS
Clinical samples and virus isolates. hMPV-positive specimens were obtained
from nasopharyngeal samples collected from patients with symptoms of respira-
tory tract disease (13, 15). Viruses were grown on tertiary monkey kidney (tMK)
cells, and the isolates were stored at70°C. For each of the four genetic lineages
of hMPV, a single virus isolate was selected as the prototype isolate (16). RNA
from these prototype virus isolates was used to test the designed Taqman primers
and probes. The nucleoprotein sequence of lineage A1, strain NL/1/00 can be
obtained from the GenBank database (accession number AF371337) (see below
for the accession numbers of the sequences submitted for this study).
For validation of the Taqman RT-PCR assay, we used nasopharyngeal samples
that were collected in the 2000-2001 and 2001-2002 winter seasons in The
Netherlands and that had previously tested positive (n 38) or negative (n 54)
for hMPV by virus isolation or a standard RT-PCR assay based on the L gene
(15). Specificity tests were performed on RNA isolated from stocks of other
RNA viruses, including measles virus, mumps virus, simian virus 5, Newcastle
disease virus, respiratory syncytial viruses A and B, avian pneumoviruses A, B,
and C, human parainfluenza viruses 1, 2, 3, and 4, and influenza viruses A and B.
Generation of these virus stocks and RNA isolation were performed as described
before (7).
Conventional end-point RT-PCR and DNA blotting. The conventional end-
point RT-PCR assay targeting a 170-bp fragment of the L gene of hMPV was
performed with the following primer set: L-6 (5-CATGCCCACTATAAAAG
GTCAG-3) and L-7 (5-CACCCCAGTCTTTCTTGAAA-3). The reaction
mixture (total volume, 50 l) contained 5 l of RNA, 50 mM Tris-Cl (pH 8.5),
50 mM NaCl, 4 mM MgCl2, 2 mM dithiothreitol, 600 M deoxynucleoside
triphosphates, 200 nM each primer, 20 U of RNasin, 5 U of Taq polymerase
(Perkin-Elmer), and 10 U of avian myeloblastosis virus RT (Promega, Leiden,
The Netherlands). The RT-PCR parameters were as follows: 60 min at 42°C; 7
min at 95°C; 40 cycles of 1 min at 95°C, 2 min at 45°C, and 3 min at 72°C; and
a final incubation at 72°C for 10 min.
PCR products were detected by transferring a 10-l PCR sample to a Hybond
Nmembrane (Amersham Pharmacia Biotech Benelux, Roosendaal, The Neth-
erlands) and then hybridizing the sample with a biotin-labeled probe (5-CTGT
TAATATCCCACACCAGTGGCATGC-3) as described before (7). DNA frag-
ments were visualized by exposing the blot to X-ray film.
RNA isolation and generation of cDNA. RNA was isolated with a High Pure
RNA isolation kit (Roche Diagnostics, Almere, The Netherlands) according to
the manufacturer’s instructions. A 5-l RNA sample was used for the generation
of cDNA with specific primers and Superscript III RT enzyme (Invitrogen,
Breda, The Netherlands) in a final volume of 20 l at 55°C according to the
manufacturer’s instructions. For specificity tests with RNA from other respira-
tory viral agents, cDNA was generated with random-hexamer primers (Promega)
at 50°C. Aliquots of 5 l of cDNA were used for each real-time PCR. All
real-time RT-PCR assays were performed by using two-step reactions, except for
experiments in which the limits of detection of the NL-N and ALT-N assays were
compared by using runoff transcripts (see below).
Generation of RNA runoff transcripts. RNA runoff transcripts were made to
generate a standard curve for the quantitation of RNA copy numbers. The
nucleoprotein sequences of the prototype hMPV strains were cloned into pCITE
(Novagen, Madison, Wis.) under the control of a T7 promoter. Runoff tran-
scripts were generated by using the Riboprobe T7 system (Promega, Leiden, The
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Netherlands) according to the manufacturer’s instructions. RNA runoff tran-
scripts were checked by gel electrophoresis and quantitated by measuring the
A260 with a spectrophotometer.
Design of oligonucleotides and probes. Two sets of Taqman primers and
probes (NL-N and ALT-N assays) were designed to identify all four genetic
lineages of hMPV on the basis of sequence information for the nucleoprotein
gene from 53 hMPV-positive clinical specimens. All four genetic lineages of
hMPV were present within the panel of isolates. To identify conserved regions in
the hMPV nucleoprotein gene and to identify the mismatches of the tested
primers and probes with their respective target sequences, entropy plots were
created with the BioEdit software package (available through http://www.mbio
.ncsu.edu/BioEdit/bioedit.html). The selected primers and probes were located
within the most conserved regions of the nucleoprotein gene in all sequences.
The sequences of the primers and probe used for the ALT-N assay were as
follows: primer ALT-N-forward (5-CAACAACATAATGCTAGGACATGTA
TC-3), primer ALT-N-reverse (5-CCGAGAACAACACTAGCAAAGTTG-
3), and probe ALT-N-probe (5-FAM-TGGTGCGAGAAATGGGTCCTGAA
TCTGG-3BHQ_1-3). The sequences for the NL-N assay were as follows: primer
NL-N-forward (5-CATATAAGCATGCTATATTAAAAGAGTCTC-3), primer
NL-N-reverse (5-CCTATTTCTGCAGCATATTTGTAATCAG-3), and probe
NL-N-probe (5-FAM-TGYAATGATGAGGGTGTCACTGCGGTTG-TAMR
A-3, in which Y is either a C or a T residue).
Real-time RT-PCR assays. The real-time RT-PCR assays with viral RNA
runoff transcripts to compare the NL-N and ALT-N assays were performed as
one-step reactions with a single tube and a final volume of 50 l containing 10 l
of RNA, 300 nM each primer, 200 nM probe, 5 mM MgCl2, 10 U of StrataScript
RT, and 2.5 U of SureStart Taq DNA polymerase. Cycling parameters were as
follows: 30 min at 48°C, 5 min at 95°C, and 45 cycles of 30 s at 95°C and 1 min
at 60°C. Amplification and detection of RNA from virus isolates or clinical
specimens were performed with an ABI Prism 7000 Taqman machine (Applied
Biosystems) but with a separate RT step (see above). Each PCR mixture (total
volume, 25 l) contained Taqman universal PCR master mix (Applied Biosys-
tems), 5 l of cDNA, forward primer (500 nM NL-N-forward or 300 nM ALT-
N-forward), reverse primer (250 nM NL-N-reverse or 300 nM ALT-N-reverse),
and probe (500 nM NL-N-probe or 200 nM ALT-N-probe). Amplification pa-
rameters were 5 min of denaturation and activation at 95°C and 45 cycles of 30 s
at 95°C and 1 min at 60°C.
Nucleotide sequence accession numbers. The nucleoprotein sequences deter-
mined in this study can be obtained from the GenBank database as follows: for
lineage A2, strain NL/17/00, GenBank accession no. AY355324; for lineage B1,
FIG. 1. Hybridization blot showing detection of serial dilutions of
viral RNAs of the prototype hMPV strains from genetic lineages A1
(NL/1/00), A2 (NL/17/00), B1 (NL/1/99), and B2 (NL/1/94) by using
the conventional end-point RT-PCR assay targeting the hMPV L gene
(15). Values above the lanes indicate the amounts of virus (in TCID50)
from which RNA used in each reaction was obtained.
FIG. 2. Entropy plots of oligonucleotide-annealing sites in hMPV sequences available from the GenBank database. The sequences recognized
by the individual oligonucleotides were compared to all available hMPV sequences, and their heterogeneities are displayed as entropy values on
the x axis. A higher entropy value indicates mismatches at a particular position in the oligonucleotide with a larger number of target sequences
analyzed. The number of sequences upon which each plot was based is given in the upper right corner of each plot. Oligonucleotide positions are
given in the 5-3 direction, with position 1 being the extreme 5 nucleotide.
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strain NL/1/99, GenBank accession no. AY355328; and for lineage B2, strain
NL/1/94, GenBank accession no. AY355335.
RESULTS
Detection of hMPV by end-point RT-PCR and DNA blotting.
Upon the initial identification of hMPV, an assay including a
conventional end-point RT-PCR and hybridization with a bi-
otin-labeled probe was designed for hMPV detection on the
basis of the L gene of the hMPV genome (13). Figure 1 dem-
onstrates that the limits of detection of this assay were 0.01
50% tissue culture infective doses (TCID50s) per reaction for
the A1 prototype virus strain (NL/1/00), 0.1 TCID50 per reac-
tion for the B prototype virus strains (NL/1/99 and NL/1/94),
and 1 TCID50 per reaction for the A2 prototype virus strain
(NL/17/00) (Fig. 1). These results illustrate the variable sensi-
tivity of this assay with end-point RT-PCR and DNA blotting
for the detection of the four different lineages of hMPV. Re-
cent and more detailed information on the nucleotide se-
quences of the four known genetic lineages of hMPV indicates
that the primer and probe sequences used in this assay contain
a significant number of mismatches compared to their target
sequences (Fig. 2). These mismatches pose a risk for a low
sensitivity of this assay in detecting hMPV strains from certain
genetic lineages and may cause false-negative results. Further-
more, this assay is rather time-consuming and not amenable to
high-throughput sample processing. Therefore, real-time RT-
PCR was applied to improve the sensitivity, reliability, and
throughput for the detection of hMPV in a large number of
clinical samples.
Design of primers and probes for real-time RT-PCR. Two
sets of primers and probes (for the ALT-N and NL-N assays)
were designed to detect virus strains from all known genetic
lineages of hMPV. Primers and probes were targeted at the
most conserved sequences within the nucleoprotein gene of
hMPV and were designed to match all four genetic lineages of
hMPV. Figure 3 shows an alignment of the primer and probe
sequences with the target sequences of the prototype viruses
from all four genetic lineages of hMPV. Previously described
primer sets targeting the N (10) or L (15) gene sequences of
hMPV were based on the limited sequence information avail-
able at that time. The sequences of these primer sets and our
newly designed primer sets were compared to the hMPV se-
quences from the GenBank database and from several strains
sequenced in our laboratory. The variability between the viral
sequences and each oligonucleotide sequence was calculated
by using the entropy algorithm available from the BioEdit
software package and revealed a considerable degree of het-
erogeneity for most of the primer sets (Fig. 2). For successful
detection of viral RNA and to minimize the risk of false-
negative results, a good match of the 3 end of the primers is
of utmost importance. Only the sequence of the primer set for
the NL-N assay showed a good match with the sequences from
all available hMPV isolates. In real-time RT-PCR, a good
match of the 5 end of the probe with its target sequence is
critical for detecting the presence of viral RNA, as this probe
is degraded from the 5 end onward during amplification of the
viral target sequences. The entropy plots in Fig. 2 indicate that
the probe for the NL-N amplicon has the fewest number of
mismatches and therefore is expected to perform best for all
available amplicons.
Detection of hMPV by real-time RT-PCR with previously
described primer sets. To examine the influence of mismatches
in the previously described primers and probes in a real-time
RT-PCR setting, we tested whether they were able to detect
the four genetic lineages of hMPV. The results obtained with
serial dilutions of RNAs from the prototype viruses showed
that the primers and probes for the N (10) and L (15) gene
assays did amplify target sequences from the hMPV A lineage
in our real-time RT-PCR setting but not from viruses of the B
lineage (Fig. 4). Hence, the L and N gene assay primers and
probes may be of use for conventional RT-PCR (Fig. 1) and
for the LightCycler platform (10), respectively, but not for
Taqman real-time RT-PCR.
Comparison of NL-N and ALT-N assays. The newly de-
signed assays (NL-N and ALT-N assays) were tested for their
sensitivities as real-time RT-PCR assays by using serially di-
FIG. 3. Alignment of sequences of primers and probes for the NL-N and ALT-N assays with the target sequences of the four prototype hMPV
strains. Residue Y in the third position of the NL-N probe represents either a C or a T.
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luted RNAs obtained from the four hMPV prototype strains
(Fig. 5, top panels). Identical RNA aliquots were used in both
the NL-N and the ALT-N assays. With both assays, we were
able to detect viral RNAs from all four prototype strains, but
the ALT-N assay showed more variation in the efficiency of
detection of the four prototype strains. The NL-N assay, on the
other hand, proved to be equally efficient in detecting all four
prototype strains. The detection of RNAs from the hMPV
prototype strains was maintained up to a dilution factor of
106-fold by the NL-N assay (Fig. 5, top left panel). Further
dilution did not result in a positive signal for any of the strains.
The approximate limits of detection of the NL-N assay were
calculated to be at least 0.006 TCID50 for the A2 prototype
hMPV and 0.01 TCID50 for the other prototype viruses. For
the ALT-N assay, viral RNAs could be detected up to a dilu-
tion of 104-fold for the A1 prototype virus and up to a dilution
of 105-fold for the other three prototype viruses (Fig. 5, top
right panel).
Quantitated RNA runoff transcripts from the nucleoprotein
genes of the prototype strains were also used to determine the
sensitivities and limits of detection of both assays (Fig. 5, bot-
tom panels). A comparison confirmed that both assays were
able to detect target sequences from all four genetic lineages of
hMPV, although serial dilutions of the RNA runoff transcripts
showed that the ALT-N assay was less sensitive for detecting
sequences of the A1 and A2 prototype virus strains (Fig. 5,
bottom right panel). The NL-N assay could easily detect 50
RNA copies from each of the four prototype hMPV strains
with equal efficiencies (as indicated by the similar Ct values
[first PCR cycle at which a positive signal was detected for each
sample] for each dilution of the different RNA samples). Fur-
ther dilution of the target RNAs from the A1 and B1 prototype
virus strains to five copies still yielded a positive signal in most
experiments (data not shown). Considering errors in quantita-
tion of the RNA runoff transcript copy numbers and pipetting
errors in making serial dilutions, we estimate the limit of de-
tection of the NL-N assay to be about 5 to 10 copies per
reaction. The ALT-N assay could detect 50 RNA copies from
the B1 and B2 prototype virus strains but was much less effi-
cient in detecting RNA copies from the A1 and A2 prototype
virus strains (as indicated by the higher Ct values for each
dilution and the lower sensitivity in detecting diluted RNA).
Specificity of the NL-N assay. To test whether the primers
and probe designed for the NL-N assay were specific for
hMPV, we used RNAs from 15 other common respiratory viral
agents as templates for real-time RT-PCR analysis. These tem-
plates were isolated from stocks of measles virus, mumps virus,
simian virus 5, Newcastle disease virus, respiratory syncytial
viruses A and B, avian pneumoviruses A, B, and C, human
parainfluenza viruses 1, 2, 3, and 4, and influenza viruses A and
B. The hMPV A1 prototype strain was used as a positive
control sample. For this experiment, cDNAs from all samples
were generated with random-hexamer primers in a separate
RT step. None of the RNA templates isolated from the non-
hMPV strains resulted in a positive signal, confirming that the
designed primers and probe were specific for hMPV (data not
shown).
We next used the newly developed real-time RT-PCR NL-N
assay to detect hMPV RNA in clinical samples that had pre-
viously been found to be either positive or negative for hMPV
by the conventional RT-PCR specific for the L gene (15). A
panel of 38 clinical samples that had previously been found to
be positive were all confirmed to be positive by our real-time
RT-PCR NL-N assay. An additional panel of 54 samples that
had previously been found to be negative did not give a posi-
tive signal in our new assay (data not shown). These results
indicate that our new assay is at least as sensitive as conven-
tional RT-PCR targeting of the L gene of hMPV and does not
produce false-negative results.
DISCUSSION
The implications of the discovery of hMPV for respiratory
tract disease, especially in young children and immunocompro-
mised individuals, emphasize the need for a reliable and sen-
sitive assay for detecting this virus. Recently, it became clear,
on the basis of sequence analyses of the hMPV genome, that
hMPV strains circulating around the world can be divided into
two main genetic lineages (A and B) representing two sero-
types and each comprising two sublineages (A1, A2, B1, and
B2) (1, 16). Upon the initial identification of hMPV, a set of
primers and a probe targeting the L gene sequence of hMPV
FIG. 4. Real-Time RT-PCR amplification in the N (A) and L
(B) gene assays of serially diluted RNAs of prototype hMPV strains.
The values on the x axes indicate the amounts of RNA per reaction,
ranging from undiluted (1e0) to millionfold diluted (1e6) RNAs.
Ct values on the y axes indicate the first PCR cycle at which a positive
signal was detected for each sample. Black circles and triangles rep-
resent the lineage A1 (NL/1/00) and A2 (NL/17/00) prototype virus
strains, respectively. No amplification of viral RNA from lineage B
viruses was detected in these experiments. Error bars indicate standard
deviations for triplicate samples.
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were designed and shown to be able to amplify and detect
hMPV strains from all four genetic lineages in a conventional
end-point RT-PCR setting. This assay, however, was not
equally sensitive for virus strains from all four known genetic
lineages. Furthermore, because the primers and probe used in
this assay were designed on the basis of limited sequence data,
the oligonucleotide sequences showed a considerable number
of mismatches compared to their target sequences, posing a
risk of obtaining false-negative results.
Here we describe the development and evaluation of a real-
time RT-PCR assay (NL-N assay) that can detect the four
genetic lineages of hMPV described to date with comparable
sensitivities. Primers and a probe were designed on the basis of
a wide range of hMPV sequences available from public data-
bases with a minimum number of mismatches. Figures 2 and 3
show that for the NL-N assay primers, a few mismatches do
exist, but since these are mainly in the 5 end, they probably
have little impact on PCR amplification. The probe was chosen
such that any mismatches were at the 3 end and not at the 5
end of the probe. This choice ensures that the 5 end of the
probe is firmly attached to its target sequence during PCR and
is thus efficiently hydrolyzed by the endonuclease activity of the
DNA polymerase.
The entropy plots showing the mismatches of the primer and
probe sequences with their target sequences (Fig. 2) also indi-
cate why the previously described primers and probes targeting
the N (10) and L (15) gene sequences of hMPV were not
successful in efficiently amplifying RNAs from all four proto-
type hMPV strains in our experimental real-time RT-PCR
setup. As both of these assays were developed on the basis of
limited sequence information primarily available for lineage A
strains of hMPV, mismatches between primer and probe se-
quences and their respective target sequences were most se-
vere for lineage B strains. These multiple mismatches are most
likely the reason why we were not able to amplify RNAs from
lineage B prototype virus strains (NL/1/99 and NL/1/94) with
these primers in our Taqman setup (Fig. 4). The inefficiency of
both assays is also illustrated by the high Ct values (35 cycles)
and the high number of cycles needed to produce a clear
signal. It should be noted that the N gene primers described by
Mackay et al. (10) were originally designed for use with a
LightCycler platform. We cannot rule out the possibility that
these primers in LightCycler assays can detect all four genetic
lineages of hMPV. With a Taqman platform, the relatively low
annealing temperature of the probe (60°C) may result in
inefficient hydrolysis of the probe and poor detection of the
amplified product. Although the L gene assay did not perform
well in the Taqman real-time RT-PCR setting, Fig. 1 shows
FIG. 5. Real-time RT-PCR amplification of serially diluted RNAs from virus stocks (top panels) and RNA runoff transcripts from the
nucleoprotein gene (bottom panels) of four prototype hMPV strains inthe NL-N assay (left panels) and the ALT-N assay (right panels). Black
symbols are the same as those defined in the legend to Fig. 4. Grey circles and triangles represent the lineage B1 (NL/1/99) and B2 (NL/1/94)
prototype virus strains, respectively. The values on the x axes in the top panels indicate the serial dilutions of RNA per reaction, ranging from 0-fold
(1e) to millionfold (1e) dilutions. The values on the x axes in the bottom panels indicate the numbers of RNA molecules per reaction, ranging
from 50 million (5e7) to 50 (5e1). Error bars indicate standard deviations. Ct, threshold cycle.
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that the primers and probe used for this assay are capable of
detecting target sequences for all prototype hMPV strains in a
conventional end-point RT-PCR setting. This result suggests
that the mismatches in the L gene primers had much less of an
effect in the conventional RT-PCR assay than in the real-time
RT-PCR assay. This discrepancy is probably the result of the
lower annealing temperature (45°C) used in the conventional
RT-PCR setting, where the level of binding of the primers to
the target sequence was apparently sufficient for PCR ampli-
fication.
In general, real-time RT-PCR assays have a very high level
of specificity. Apart from the primers, the specificity of the
reaction is also determined by binding of the probe to its
specific target sequence. The specificity of the assay is espe-
cially important, as clinical samples from patients with symp-
toms of respiratory disease may contain any of a number of
different respiratory viral agents. The NL-N assay did not give
any positive signal when RNAs from other respiratory viruses
were used as templates, indicating that the assay is indeed
specific for hMPV. The assay performed well with clinical
samples from patients with symptoms of respiratory disease.
From a panel of 92 clinical samples, the assay could identify all
samples that had been shown to be hMPV positive by previ-
ously conducted conventional RT-PCR analysis or virus isola-
tion. Samples that had been shown to be negative by these
previous tests did not yield a positive signal in our real-time
RT-PCR assay. These results indicate that the risk of misin-
terpretating clinical samples, both as false-negative results and
as false-positive results, is very limited with this real-time RT-
PCR assay.
The main reason for developing this new assay was to de-
velop a single test that can identify virus strains from all four
hMPV genetic lineages with similar sensitivities. By testing
serial dilutions of RNAs from four prototype hMPV strains, we
concluded that the assay worked equally well for all four ge-
netic lineages of hMPV, with a limit of detection of about 0.01
TCID50. Whereas TCID50 is an indication of the number of
infectious viral particles, it may be a poor measure of viral
genomic RNA copy numbers. To obtain a more accurate in-
dication of the limit of detection of our NL-N assay, we gen-
erated RNA runoff transcripts from the nucleoprotein gene of
the A1 and B1 prototype hMPV strains. Upon quantitation,
serial dilutions of the RNA runoff transcripts tested in our
assay indicated that the limit of detection of our assay was
about 5 to 10 copies of the RNA target sequence.
In conclusion, we have developed a real-time RT-PCR assay
for the amplification and detection of RNA of hMPV from all
four genetic lineages. The results show that the sensitivities of
the assay for strains of hMPV from all four genetic lineages are
similar and that the assay is approximately 10-fold more sen-
sitive than the previously described conventional RT-PCR as-
say targeting the hMPV L gene sequence (15). Our assay also
proved to be faster and highly specific and can be used for
future implementation in a diagnostic setting.
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